Hebert Robert P 4
4 · CPEX Pharmaceuticals, Inc. · Filed Apr 7, 2011
Insider Transaction Report
Form 4
Hebert Robert P
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2011-04-05−1,000→ 0 totalExercise: $11.06Exp: 2014-05-01→ Common Stock (1,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−60,000→ 0 totalExercise: $17.20Exp: 2018-07-01→ Common Stock (60,000 underlying) - Exercise/Conversion
Common Stock
2011-04-05+65,205→ 73,183 total - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−1,100→ 0 totalExercise: $9.01Exp: 2013-05-21→ Common Stock (1,100 underlying) - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−1,000→ 0 totalExercise: $6.63Exp: 2015-04-06→ Common Stock (1,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2011-04-05−2,105→ 0 totalExercise: $10.00Exp: 2019-09-29→ Common Stock (2,105 underlying) - Tax Payment
Common Stock
2011-04-05$27.25/sh−39,668$1,080,953→ 33,515 total - Disposition to Issuer
Common Stock
2011-04-05−33,515→ 0 total
Footnotes (3)
- [F1]1,100 options had an exercise price of $9.0142, 1,000 options had an exercise price of $11.0613, 1,000 options had an exercise price of $6.6350, 60,000 had an exercise price of $17.2050 and 2,105 options had an exercise price of $10.000.
- [F2]Pursuant to the Agreement and Plan of Merger between CPEX Pharmaceuticals, Inc., FCB I Holdings Inc. and FCB I Acquisition Corp. dated January 3, 2011 (the "Merger Agreement"), each share of CPEX common stock was exchanged for $27.25.
- [F3]This option is fully vested.